JP2018537128A - 骨髄腫の治療または進行のモニタリング - Google Patents

骨髄腫の治療または進行のモニタリング Download PDF

Info

Publication number
JP2018537128A
JP2018537128A JP2018548246A JP2018548246A JP2018537128A JP 2018537128 A JP2018537128 A JP 2018537128A JP 2018548246 A JP2018548246 A JP 2018548246A JP 2018548246 A JP2018548246 A JP 2018548246A JP 2018537128 A JP2018537128 A JP 2018537128A
Authority
JP
Japan
Prior art keywords
individual
kras
nras
cell
mutations
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018548246A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018537128A5 (enExample
Inventor
スペンサー アンドリュー
スペンサー アンドリュー
ミスラプラブー スリドゥルガ
ミスラプラブー スリドゥルガ
Original Assignee
アルフレッド ヘルス
アルフレッド ヘルス
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2015905013A external-priority patent/AU2015905013A0/en
Application filed by アルフレッド ヘルス, アルフレッド ヘルス filed Critical アルフレッド ヘルス
Publication of JP2018537128A publication Critical patent/JP2018537128A/ja
Publication of JP2018537128A5 publication Critical patent/JP2018537128A5/ja
Priority to JP2021165655A priority Critical patent/JP2022000059A/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Indole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
JP2018548246A 2015-12-03 2016-12-02 骨髄腫の治療または進行のモニタリング Pending JP2018537128A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021165655A JP2022000059A (ja) 2015-12-03 2021-10-07 骨髄腫の治療または進行のモニタリング

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
AU2015905013 2015-12-03
AU2015905013A AU2015905013A0 (en) 2015-12-03 Monitoring treatment or progression of myeloma
AU2016903019 2016-08-01
AU2016903019A AU2016903019A0 (en) 2016-08-01 Monitoring treatment or progression of myeloma (2)
PCT/AU2016/051191 WO2017091865A1 (en) 2015-12-03 2016-12-02 Monitoring treatment or progression of myeloma

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021165655A Division JP2022000059A (ja) 2015-12-03 2021-10-07 骨髄腫の治療または進行のモニタリング

Publications (2)

Publication Number Publication Date
JP2018537128A true JP2018537128A (ja) 2018-12-20
JP2018537128A5 JP2018537128A5 (enExample) 2019-12-26

Family

ID=58796005

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018548246A Pending JP2018537128A (ja) 2015-12-03 2016-12-02 骨髄腫の治療または進行のモニタリング
JP2021165655A Pending JP2022000059A (ja) 2015-12-03 2021-10-07 骨髄腫の治療または進行のモニタリング

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021165655A Pending JP2022000059A (ja) 2015-12-03 2021-10-07 骨髄腫の治療または進行のモニタリング

Country Status (8)

Country Link
US (1) US20180282820A1 (enExample)
EP (1) EP3384050A4 (enExample)
JP (2) JP2018537128A (enExample)
KR (1) KR20180088690A (enExample)
CN (1) CN108603232A (enExample)
AU (1) AU2016363113A1 (enExample)
CA (1) CA3007426A1 (enExample)
WO (1) WO2017091865A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023501376A (ja) * 2019-11-06 2023-01-18 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 核酸分子を分析するための方法およびシステム
JP2023509119A (ja) * 2019-12-26 2023-03-07 ペ エム ベ 協働照射装置

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11322224B2 (en) 2010-05-18 2022-05-03 Natera, Inc. Methods for non-invasive prenatal ploidy calling
US12221653B2 (en) 2010-05-18 2025-02-11 Natera, Inc. Methods for simultaneous amplification of target loci
US20190010543A1 (en) 2010-05-18 2019-01-10 Natera, Inc. Methods for simultaneous amplification of target loci
US10316362B2 (en) 2010-05-18 2019-06-11 Natera, Inc. Methods for simultaneous amplification of target loci
US11939634B2 (en) 2010-05-18 2024-03-26 Natera, Inc. Methods for simultaneous amplification of target loci
US9677118B2 (en) 2014-04-21 2017-06-13 Natera, Inc. Methods for simultaneous amplification of target loci
US12152275B2 (en) 2010-05-18 2024-11-26 Natera, Inc. Methods for non-invasive prenatal ploidy calling
BR112013020220B1 (pt) 2011-02-09 2020-03-17 Natera, Inc. Método para determinar o estado de ploidia de um cromossomo em um feto em gestação
US20140100126A1 (en) 2012-08-17 2014-04-10 Natera, Inc. Method for Non-Invasive Prenatal Testing Using Parental Mosaicism Data
US20180173846A1 (en) 2014-06-05 2018-06-21 Natera, Inc. Systems and Methods for Detection of Aneuploidy
US11479812B2 (en) 2015-05-11 2022-10-25 Natera, Inc. Methods and compositions for determining ploidy
RU2760913C2 (ru) 2016-04-15 2021-12-01 Натера, Инк. Способы выявления рака легкого
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
GB201618485D0 (en) 2016-11-02 2016-12-14 Ucl Business Plc Method of detecting tumour recurrence
WO2018134254A1 (en) 2017-01-17 2018-07-26 Heparegenix Gmbh Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
CA3067637A1 (en) 2017-06-20 2018-12-27 The Medical College Of Wisconsin, Inc. Assessing transplant complication risk with total cell-free dna
US11810672B2 (en) 2017-10-12 2023-11-07 Nantomics, Llc Cancer score for assessment and response prediction from biological fluids
CN107881233A (zh) * 2017-10-31 2018-04-06 天津协和华美医学诊断技术有限公司 一种检测骨髓瘤相关基因群的检测试剂盒
US12084720B2 (en) 2017-12-14 2024-09-10 Natera, Inc. Assessing graft suitability for transplantation
US12024738B2 (en) 2018-04-14 2024-07-02 Natera, Inc. Methods for cancer detection and monitoring
EP3784805A1 (en) * 2018-04-23 2021-03-03 Inivata Limited Method for predicting and monitoring response to an immune checkpoint inhibitor
US12234509B2 (en) 2018-07-03 2025-02-25 Natera, Inc. Methods for detection of donor-derived cell-free DNA
BR112021002189A2 (pt) 2018-08-08 2021-05-04 Inivata Ltd. método de sequenciamento que usa pcr multiplex de replicação variável
CN113874525A (zh) * 2018-10-29 2021-12-31 分子听诊器公司 使用无细胞信使rna的骨髓表征
WO2020092646A1 (en) * 2018-10-30 2020-05-07 Molecular Stethoscope, Inc. Cell-free rna library preparations
WO2020131955A1 (en) * 2018-12-17 2020-06-25 The Medical College Of Wisconsin, Inc. Assessing risk with total cell-free dna
US11931674B2 (en) 2019-04-04 2024-03-19 Natera, Inc. Materials and methods for processing blood samples
US20210087638A1 (en) * 2019-09-23 2021-03-25 Dana-Farber Cancer Institute, Inc. Next-generation sequencing assay for genomic characterization and minimal residual disease detection in the bone marrow, peripheral blood, and urine of multiple myeloma and smoldering myeloma patients
CN112760290A (zh) * 2019-10-21 2021-05-07 郑州大学 携带突变的肿瘤驱动基因的干细胞及其用途
CN112698037B (zh) * 2021-03-25 2021-06-25 北京积水潭医院 一种检测多发性骨髓瘤治疗效果的抗体组合物及其试剂盒和应用
CN116679065B (zh) * 2023-07-31 2023-11-14 北京大学人民医院 检测试剂的应用、多发性骨髓瘤治疗预后预测方法及产品

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014151117A1 (en) * 2013-03-15 2014-09-25 The Board Of Trustees Of The Leland Stanford Junior University Identification and use of circulating nucleic acid tumor markers
JP2014533114A (ja) * 2011-11-11 2014-12-11 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． プロテアソーム阻害剤に応答するバイオマーカー
WO2015058176A1 (en) * 2013-10-19 2015-04-23 Trovagene, Inc. Detecting mutations in disease over time

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010019694A1 (en) * 2008-08-12 2010-02-18 The Ohio State University Research Foundation Micro-rna-based compositions and methods for the diagnosis, prognosis and treatment of multiple myeloma
EP2499486A4 (en) * 2009-11-13 2013-11-27 Infinity Pharmaceuticals Inc COMPOSITIONS, KITS, AND METHODS FOR IDENTIFICATION, EVALUATION, PREVENTION, AND THERAPY OF CANCER

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014533114A (ja) * 2011-11-11 2014-12-11 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． プロテアソーム阻害剤に応答するバイオマーカー
WO2014151117A1 (en) * 2013-03-15 2014-09-25 The Board Of Trustees Of The Leland Stanford Junior University Identification and use of circulating nucleic acid tumor markers
WO2015058176A1 (en) * 2013-10-19 2015-04-23 Trovagene, Inc. Detecting mutations in disease over time

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
KAEDBEY R. ET AL.: "Abstract 615: Noninvasive diagnosis of actionable mutations by deep sequencing of circulating tumor", AMERICAN ASSOCIATION FOR CANCER RESEARCH 106TH ANNUAL MEETING 2015, JPN6020029660, ISSN: 0004520785 *
LOHR J. G. ET AL.: "'Widespread genetic heterogeneity in multiple myeloma: Implications for targeted therapy'", CANCER CELL, vol. 25, no. 1, JPN6020029662, 2014, pages 91 - 101, ISSN: 0004520786 *
WALKER B. A. ET AL.: "'Mutational spectrum, copy number changes, and outcome: Results of a sequencing study of patients wi", JOURNAL OF CLINICAL ONCOLOGY, vol. 33, no. 33, JPN6020029663, 20 November 2015 (2015-11-20), pages 3911 - 3920, ISSN: 0004520787 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023501376A (ja) * 2019-11-06 2023-01-18 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 核酸分子を分析するための方法およびシステム
JP2024028940A (ja) * 2019-11-06 2024-03-05 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 核酸分子を分析するための方法およびシステム
JP2023509119A (ja) * 2019-12-26 2023-03-07 ペ エム ベ 協働照射装置
JP7702053B2 (ja) 2019-12-26 2025-07-03 ペ エム ベ 協働照射装置

Also Published As

Publication number Publication date
CN108603232A (zh) 2018-09-28
AU2016363113A1 (en) 2018-06-07
WO2017091865A1 (en) 2017-06-08
KR20180088690A (ko) 2018-08-06
CA3007426A1 (en) 2017-06-08
EP3384050A1 (en) 2018-10-10
EP3384050A4 (en) 2019-07-31
US20180282820A1 (en) 2018-10-04
JP2022000059A (ja) 2022-01-04

Similar Documents

Publication Publication Date Title
JP2022000059A (ja) 骨髄腫の治療または進行のモニタリング
JP6700333B2 (ja) ヘテロ接合性の消失（ｌｏｓｓ ｏｆ ｈｅｔｅｒｏｚｙｇｏｓｉｔｙ）を評価するための方法および材料
EP3198026B1 (en) Method of determining pik3ca mutational status in a sample
US10982286B2 (en) Algorithmic approach for determining the plasma genome abnormality PGA and the urine genome abnormality UGA scores based on cell free cfDNA copy number variations in plasma and urine
CN107949642B (zh) 用于筛选实体瘤的组合物和方法
JP7626797B2 (ja) マイクロサテライト不安定性の検出
US11414710B2 (en) Compositions and methods for detecting circulating tumor DNA
WO2017112738A1 (en) Methods for measuring microsatellite instability
US20230002831A1 (en) Methods and compositions for analyses of cancer
WO2022157764A1 (en) Non-invasive cancer detection based on dna methylation changes
US20140194467A1 (en) Plasma cell disorders
US12391985B2 (en) Method of determining PIK3CA mutational status in a sample
WO2015048852A1 (en) Kits and methods for diagnosis, screening, treatment and disease monitoring
US20240084389A1 (en) Use of simultaneous marker detection for assessing difuse glioma and responsiveness to treatment
WO2017106365A1 (en) Methods for measuring mutation load
JP2024530807A (ja) Ｒｎａを用いたゲノム変化および遺伝子発現変化の検出および定量化の方法
JP2022504237A (ja) 処置に対する反応をモニタリングする方法
HK1241934A1 (en) Method of determining pik3ca mutational status in a sample
HK1241934B (en) Method of determining pik3ca mutational status in a sample

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191114

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20191114

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20200731

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200818

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20201117

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210218

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20210608